Delivery Order SPE2DR25D1053-SPE2DR26FT975
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,768.16 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product used for treating autoimmune conditions. The contract was awarded on November 5, 2025, with an ultimate completion date of November 6, 2025, and is structured as a firm fixed price delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $4,656.85 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a injectable medication used to treat autoimmune conditions. This contract, awarded on October 21, 2025, with an ultimate completion date of October 22, 2025, is a firm fixed price delivery order with no set-aside designation. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a biologic medication used to treat autoimmune conditions. The contract is valued at $6,817.16 and is classified as a firm fixed-price delivery order with an ultimate completion date of October 23, 2025. The award uses no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a pharmaceutical product for immune-mediated conditions. Awarded on August 10, 2025, with an ultimate completion date of August 11, 2025, this firm fixed price delivery order represents a competitive award with no set-aside designation. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a biologic medication used primarily for autoimmune conditions. This firm fixed-price delivery order, valued at $7,754.51, was competitively awarded with no set-aside designation and carries an ultimate completion date of June 25, 2025. The order will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, the company's headquarters...
- The Defense Logistics Agency (DLA) awarded a $1,510.60 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, an immunosuppressant medication used to treat autoimmune diseases. This firm fixed-price delivery order, awarded on August 26, 2025, with an ultimate completion date of August 27, 2025, represents a single-transaction purchase under a larger contract vehicle. The award was made on a competitive, non-set-aside basis to AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $1,989.76 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a pharmaceutical product used to treat inflammatory conditions. The award, issued on October 27, 2025, with an ultimate completion date of October 28, 2025, carries a firm fixed price and represents a non-competitive delivery order. Performance will occur at the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $1,227.99 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on November 7, 2025, with completion scheduled for November 10, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HUMIRA is a biologic immunosuppressant medication used to treat various inflammatory and autoimmune conditions,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a prescription medication used to treat autoimmune conditions, with a contract value of $1,132.95. Awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, this delivery order utilizes firm fixed price pricing and was competitively awarded with no set-aside designation. The product will be performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a $1,510.60 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mL, a biologic medication used to treat autoimmune conditions. This is a firm fixed-price delivery order with an ultimate completion date of April 24, 2025, issued under a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions provider for federal...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT975Delivery Order
The Defense Logistics Agency awarded a $36,664.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls, a biologic immunosuppressant medication used to treat autoimmune conditions. Awarded on November 18, 2025, with an ultimate completion date of November 19, 2025, this delivery order carries no set-aside designation and was competitively awarded. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables the company to supply a comprehensive portfolio of pharmaceutical products and medical supplies to support military healthcare systems worldwide, including the Defense Health Agency and U.S. Coast Guard. The arrangement reflects DLA's strategy of leveraging prime vendor partnerships to ensure reliable access to critical medications across multiple therapeutic domains for the federal healthcare enterprise.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $36.7k | 11/18/25 |